BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 29644505)

  • 1. Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.
    Asnani A
    Curr Oncol Rep; 2018 Apr; 20(6):44. PubMed ID: 29644505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
    Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
    Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicities associated with immune checkpoint inhibitors.
    Yang S; Asnani A
    Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of Immune Therapy.
    Ganatra S; Parikh R; Neilan TG
    Cardiol Clin; 2019 Nov; 37(4):385-397. PubMed ID: 31587780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Toxicities of CAR T-cell Therapy.
    Patel NP; Doukas PG; Gordon LI; Akhter N
    Curr Oncol Rep; 2021 May; 23(7):78. PubMed ID: 33937946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
    Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
    Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicities of novel cancer immunotherapies.
    Stein-Merlob AF; Rothberg MV; Ribas A; Yang EH
    Heart; 2021 Nov; 107(21):1694-1703. PubMed ID: 33722826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.
    Patel M; Hudson O; Han J; Kondapalli L; Arora G; Hawi R; Andrikopoulou E; Estes C; Johnson AM; Lenneman C
    Curr Treat Options Oncol; 2023 Nov; 24(11):1489-1503. PubMed ID: 37624557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular immune-related adverse events: Evaluation, diagnosis and management.
    Liu Y; Wu W
    Asia Pac J Clin Oncol; 2020 Aug; 16(4):232-240. PubMed ID: 32129935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
    Liu Y; Chen Y; Zeng Z; Liu A
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
    Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
    Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy.
    Jamal FA; Khaled SK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):130-132. PubMed ID: 32016789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitor-Associated Myocarditis.
    Ganatra S; Neilan TG
    Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.
    Lipe DN; Rajha E; Wechsler AH; Gaeta S; Palaskas NL; Alhajji Z; Viets-Upchurch J; Chaftari P
    Am J Emerg Med; 2021 Dec; 50():51-58. PubMed ID: 34274878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies.
    Gutierrez C; Rajendram P; Pastores SM
    Crit Care Clin; 2021 Jan; 37(1):47-67. PubMed ID: 33190775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity of immune checkpoint inhibitors: An updated review.
    Behravesh S; Shomali N; Danbaran GR; Aslani S; Hemmatzadeh M; Hosseinzadeh R; Gowhari-Shabgah A; Mohammadi H
    Biotechnol Appl Biochem; 2022 Feb; 69(1):61-69. PubMed ID: 33289168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
    Fishman JA; Hogan JI; Maus MV
    Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.